Pegasys users may now access resources to help with reimbursement issues through Genentech
People taking Pegasys for their Polycythemia Vera, Essential Thrombocythemia or Myelofibrosis may now access resources to help with reimbursement issues through Genentech. For more information about the Genentech Patient Foundation and to learn if a patient receiving a Genentech product (such as Pegasys) is eligible to receive support, please visit www.gene.com/patients/patient-foundation or call the Patient Resource Center at 877-GENENTECH.
Pegasys is a form of pegylated interferon that is used off label by many individuals living with a myeloproliferative neoplasm. As it is accessed off-label, many have dealt with access and reimbursement issues which have been dealt with individually as patients. MPNRF has shared the documentation that has helped with access previous here:
- How one patient persuaded her insurance company to cover her Pegasys
- Background on the compendia and off-label use in MPNs
Currently, there is another formulation of interferon (Ropeginterferon) being tested for MPNs. It has been approved (as Besremi) in Europe but is not yet approved by the FDA. Here is a 2018 presentation by Dr. Srdan Versvosek about ropeginterferon.
We will continue to share all relevant drug and research news as it becomes available.